Showing 5551-5560 of 8891 results for "".
- Severe AD Linked to CV Risk in Large Trialhttps://practicaldermatology.com/news/severe-ad-linked-to-cv-risk-in-large-trial/2457748/Eczema now joins the list of inflammatory conditions linked to cardiovascular risk. British researchers report that individuals with severe eczema may be at greater risk for heart attack, stroke and atrial fibrillation. Their study appears in the
- Psoriatic Arthritis Awareness Project Launcheshttps://practicaldermatology.com/news/psoriatic-arthritis-awareness-project-launches/2457751/In recognition of Psoriatic Arthritis Action Month, the National Psoriasis Foundation (NPF), in collaboration with Novartis Pharmaceuticals Corporation, has premiered the Psoriatic Arthritis (PsA) Awareness Project. The PsA Awareness Project is a set of patient films that highlight the impo
- Dr. Daniel Siegel Joins MedX's Medical Advisory Boardhttps://practicaldermatology.com/news/dr-daniel-siegel-joins-medxs-medical-advisory-board/2457754/Daniel Siegel, MD, Clinical Professor of Dermatology at SUNY Downstate in Brooklyn, New York, and a former President of the American Academy of Dermatology has joined the Medical Advisory Board of MedX Health Corp. “Daniel’s academic and practical business experience is impres
- FDA Approves Lilly's Taltz for Label Update to Treat Psoriasis Involving the Genital Areahttps://practicaldermatology.com/news/fda-approves-lillys-taltz-for-label-update-to-treat-psoriasis-involving-the-genital-area/2457755/The FDA has approved a label update for Taltz (ixekizumab) injection 80 mg/mL to include data in psoriasis involving the genital area. Eli Lilly and Company's Taltz is the first treatment FDA approved for moderate-to-severe plaque psoriasis that includes such data in its label. Taltz was
- New Guidelines May Slightly Increase Reliability, Accuracy of Melanoma Diagnoseshttps://practicaldermatology.com/news/new-guidelines-may-slightly-increase-reliability-accuracy-of-melanoma-diagnoses/2457759/New guidelines may slightly increase reliability and accuracy of melanoma diagnoses, a new study in JAMA Network Open shows. The American Joint Committee on Cancer recently updated its guidelines for melanoma, and the study researchers found that when pathologists used the new gu
- Glenmark Pharmaceuticals Presents New Data on GBR 830, an Investigational, Anti-OX40 Monoclonal Antibody, at IID Meetinghttps://practicaldermatology.com/news/glenmark-pharmaceuticals-presents-new-data-on-gbr-830-an-investigational-anti-ox40-monoclonal-antibody-at-iid-meeting/2457760/Glenmark Pharmaceuticals shared data from a Phase 2a, proof-of-concept study of GBR 830, an investigational, anti-OX40 monoclonal antibody being studied for the treatment of moderate-to-severe atopic dermatitis (AD), that were presented at the International Investigative Dermatology Meeting (IID)
- ASDS: Skin Cancer Treatment Ranks as Most-Performed Procedure of 2017https://practicaldermatology.com/news/asds-skin-cancer-treatment-ranks-as-most-performed-procedure-of-2017/2457761/The American Society for Dermatologic Surgery (ASDS) members performed nearly 12 million medically necessary and cosmetic procedures in 2017 – over 10 percent more than 2016 and doubling since 2012. For the sixth year in a row, the 2017 ASDS Survey on Dermatologic Procedures reveale
- Dupixent Improves Moderate-to-Severe Atopic Dermatitis in Adolescentshttps://practicaldermatology.com/news/dupixent-improves-moderate-to-severe-atopic-dermatitis-in-adolescents/2457764/DUPIXENT (dupilumab) performed well in a Phase 3 Trial of inadequately controlled moderate-to-severe atopic dermatitis in adolescents, Regeneron and Sanofi report. In the trial, treatment with DUPIXENT as monotherapy significantly improved measures of overall disease severity, skin c
- National Psoriasis Foundation Honors Dr. Jerry Bagel with Excellence in Leadership Awardhttps://practicaldermatology.com/news/national-psoriasis-foundation-honors-dr-jerry-bagel-with-excellence-in-leadership-award/2457766/Jerry Bagel, MD, an internationally recognized expert in the treatment of psoriasis and founder of Windsor Dermatology and Psoriasis Treatment Center of Central New Jersey, will receive the Excellence in Leadership Award from the National Psoriasis Foundation (NPF) next month. For more th
- Aclaris to Support Symposium on JAK Inhibitors at the International Investigative Dermatology 2018 Meetinghttps://practicaldermatology.com/news/aclaris-to-support-symposium-on-jak-inhibitors-at-the-international-investigative-dermatology-2018-meeting/2457767/Aclaris Therapeutics, Inc. has provided an unrestricted educational grant for the symposium on Janus Kinase (JAK) inhibitors at the International Investigative Dermatology (IID) 2018 Meeting in Orlando, FL. The symposium, titled “JAKs Be Nimble: New Applications of JAK Inhibitors in Dermato